Liver Damage and Cardiometabolic Disorders in NAFLD

Launched by UNIVERSITY OF ROMA LA SAPIENZA · Jul 25, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how liver damage and certain heart-related conditions are linked in people who have non-alcoholic fatty liver disease (NAFLD). The researchers want to learn more about factors that affect liver health, especially since liver fibrosis (scarring of the liver) is a key indicator of how serious NAFLD can become. They are looking for participants aged 18 and older who have at least one metabolic disorder, such as obesity, diabetes, high blood pressure, or high cholesterol levels.

If you join this trial, you will help researchers understand more about how these conditions interact, which may lead to better treatments in the future. However, if you consume a lot of alcohol, have certain liver infections, or other chronic diseases, you may not be eligible to participate. The trial is currently recruiting participants, and everyone, regardless of gender, can apply. Your involvement could make a significant difference in understanding NAFLD and its effects on overall health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years old or more
• • Patients with at least on of the following metabolic disorders
• • Obesity
• • Diabetes
• • Arterial hypertension
• • Dyslipidemia
• Exclusion Criteria:
• • Average daily consumption of alcohol \>20 g in women and of \>30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT;
• • presence of hepatitis B surface antigen and antibody to hepatitis C virus;
• • positive tests for autoimmune hepatitis;
• • cirrhosis and other chronic liver diseases;
• • diagnosis of oncological diseases
• • concomitant therapy with drugs known to promote liver steatosis (e.g. amiodarone);
• • other chronic infectious or autoimmune disease;